Investigators have shown that REED1 expression was elevated during stress, which in turn suppressed hippocampal synaptogenesis and induced major depressive disorder (MDD)-like behavior through mTORC1 signaling. The impact of REDD1 modulation was investigated in the preclinical setting for MDD.
Quiver Bioscience Inc. has received a strategic investment from the Porta family office (Argentina) to advance the company’s antisense oligonucleotide (ASO) therapeutic program for chromosome 15q duplication (Dup15q) syndrome. The investment will fund preclinical activities, including safety studies for candidate selection as the program advances toward clinical development.
Acute kidney injury (AKI), although sometimes reversible, is associated with an increased risk of chronic kidney disease (CKD) and progression to end-stage renal disease (ESRD). Reactive oxygen species (ROS) contribute to maladaptive repair and progression to CKD.
Kazia Therapeutics Ltd. has licensed a first-in-class SETDB1-targeted epigenetic drug development platform from QIMR Berghofer. The company acquired global rights to the SETDB1 platform, including the lead candidate MSETC, in exchange for an up-front payment and a tiered revenue-sharing structure aligned with development progress.
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and frontotemporal dementia (FTD). This fragment accumulates at synapses, disrupts glutamatergic signaling and contributes to cognitive impairment in vivo.
Researchers at the University of Edinburgh are pioneering a cancer therapy that destroys tumors from within while reawakening the immune system, using synthetic super-enhancers (SSEs) to drive targeted killing and durable protection against recurrence. The work builds on a decade of research focused on how glioblastoma stem cells (GSCs) sustain their aggressive cancer identity.
There are new data to chew over in the ongoing controversy about obesity being diagnosed as a disease from a study tracking 157,159 participants in the UK Biobank over 13 years. This shows that even in the absence of any metabolic disturbance such as elevated lipids, high blood pressure or diabetes, there is an increased risk of heart attack, stroke, peripheral arterial disease, heart failure and liver disease in people with a body mass index over 30.
Gluetacs Therapeutics (Shanghai) Co. Ltd. has discovered new proteolysis targeting chimera (PROTAC) compounds comprising a cereblon (CRBN)-binding moiety coupled to a SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 2 (SMARCA2) and SMARCA4-targeting moiety. They are designed for use in the treatment of cancer, transplant rejection, infections, diabetes, autoimmune, neurological, inflammatory and cardiovascular disorders, among others.
Chengdu Diao Pharmaceutical Group Co. Ltd. has patented new 1,2,4-triazole compounds characterized as apelin receptor (APLNR) agonists. As such, they are described as useful for the treatment of obesity, hypertension, pulmonary hypertension, heart failure, diabetes, atherosclerosis, osteoporosis and sarcopenia.
Dovetree Medicines Unus Inc. has divulged new cellular tumor antigen p53 (TP53) (Y220C mutant) stabilizers potentially useful for the treatment of cancer.
RSS
